Madam — We read with interest the article by Appleyard et al. [] on the feasibility of the adaptation of digital medicine via the use of electronic patient-reported outcome (ePRO) measures in the surveillance of prostate cancer patients on systemic treatments. This approach towards adopting non-face-to-face contact with patients on systemic anticancer treatment is prescient in view of the ongoing COVID-19 pandemic. Innovative digital health models help to mitigate the risks of transmission [].
